Impact of educational intervention on medication adherence, quality of life, knowledge attitude and practice among benign prostate hyperplasia patients: a prospective study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20205115Keywords:
Benign prostate hyperplasia, International prostate symptom score, Morisky green levin, Adherence, Knowledge, Attitude and practiceAbstract
Background: Benign prostate hyperplasia (BPH) is one of the common bothersome diseases among elderly men of age greater than 50 years. The aim of the current study was to evaluate the impact of patient counselling on quality of life (QoL), knowledge, attitude and practice (KAP) and medication adherence among patients.
Methods: A Prospective study was conducted in a total of 110 BPH patients from the department of urology for a period of 6 months. 55 patients in each group received silodosin 8 mg or tamsulosin 0.4 mg once daily. Data was collected by using a suitably designed proforma, international prostate symptom score (IPSS) and BPH impact index were used for assessing QoL, morisky green levin scale for medication adherence and a suitably designed KAP questionnaire for assessing KAP. Patients were counselled regarding the disease, drugs and lifestyle modifications using patient information leaflet.
Results: The current study found that both the Tamsulosin and Silodosin group had an improvement on QoL, IPSS Q 8 by 36% and 41.5% respectively and improvement on BII by 35.5% and 47.3% respectively. Medication adherence had significant improvement from first to second review by 12%. Significant improvement in knowledge by 80.1%, attitude by 72.7% and practice by 79.2% were observed.
Conclusions: The provision of effective counselling was found to have a profound impact on improving patient’s quality of life, medication adherence, knowledge, attitude and practice.
Metrics
References
American Urological Association Guideline: management of benign prostatic hyperplasia (BPH). 2010. Available at: http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014). Accessed on 10 May 2020.
EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020. Available at: https://uroweb.org/guideline/urological-infections/?type=archive. Accessed on 10 May 2020.
Martinez M, Satheesh M. Prostate disease. Roger Walker, Cate Whittlesea. Clinical pharmacy and therapeutics. London, Churchill Livingston. Elsevier. 2012:3:753-9
Mary L, Roohollah S. Benign Prostatic Hyperplasia. Joseph T Dipiro et al. Pharmacotherapy: A Pathophysiological Approach. 10th ed. New York, Mc GrawHill. 2017:792-833.
Roehrborn C, McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh P, Retik A, Vaughan E, Wein A (eds). Campbell's Urology, 8th edn. Saunders: Philadelphia, 2002;8:1297-336.
Kirby R, McConnell JD, Fitzpatrick JM. Griffiths K: Molecular control of prostate growth (Eds), Textbook of Benign Prostatic Hyperplasia. 1996:23-56
Mc Vary KT. AUA practice guideline committee. AUA guidelines on management of BPH, Chapter 1. Available at: www.auanet.org. Accessed on 10 May 2020.
Homma Y, Gotoh M, Yokoyama O, Masumori N, Kawauchi A, Yamanishi T, et al. Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol. 2011;18(11):741-56.
Claus G. Current Medical Therapies for Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: Achievements and Limitations. Current Medical Therapies for Men with LUTS and BPH. Rev Urol J. 2008;10(1):17-23.
Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The Measurement Committee of the American Urological Association: The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol. 1992;148:1549-57.
Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care. 1995;33:AS145-55.
Jack B, Claus GR, Paul S, Olivier H, Betsy M, Libby B et al. Effect of Dutasteride, Tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: Two-year data from the combat trial. Brit J Urol Int. 2009;103:919-26.
Deep A, Ingle GK, Kishore J. Benign Prostatic Hyperplasia: Health Seeking Behaviour of patients at a tertiary care hospital. Aus Medic J. 2010;22(3):213.
Ramesh A. Patient Counselling. G. Parthasarathi, Karin Nyfot-Hansen, Milap CN. A Textbook of Clinical Pharmacy Practice: Essential Concepts and Skills. 1st ed. Hyderabad, Orient Blackswan. 2004;1:60-71.
Mahajan P. Tadalafil therapy in symptomatic improvement of LUTS due to BPH and associated Erectile Dysfunction. J Medic Sci Clinic Resear. 2017;7:24577-82.
Nageratnam M, Latheef A. Prevalence of lower urinary tract symptoms in patients of Benign prostatic hyperplasia attending tertiary care hospital in the state of Andhra Pradesh. J NTR Univ Heal Sci. 2018;20:154-7.
Ramesh A, Kartheek S. Study of impact of patient education on health-related quality of life in benign prostatic hyperplasia (BPH) patients in a South Indian teaching Hospital. As J Pharmaceutic Clinic Resear. 2009;2:97-103.
